PEMETREXED HEMIPENTAHYDRATE for Non-small cell lung cancer: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 20 adverse event reports in the FDA FAERS database where PEMETREXED HEMIPENTAHYDRATE was used for Non-small cell lung cancer.
Most Reported Side Effects for PEMETREXED HEMIPENTAHYDRATE
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Malignant neoplasm progression | 9 | 13.2% | 2 | 1 |
| Acquired gene mutation | 7 | 10.3% | 0 | 0 |
| Pulmonary embolism | 7 | 10.3% | 0 | 0 |
| Renal impairment | 7 | 10.3% | 0 | 4 |
| Off label use | 6 | 8.8% | 0 | 0 |
| Anaemia | 5 | 7.4% | 0 | 4 |
| Death | 5 | 7.4% | 5 | 1 |
| Diarrhoea | 5 | 7.4% | 0 | 5 |
Other Indications for PEMETREXED HEMIPENTAHYDRATE
Non-small cell lung cancer metastatic (12)
Lung adenocarcinoma (10)
Lung adenocarcinoma stage iv (9)
Lung neoplasm malignant (8)
Other Drugs Used for Non-small cell lung cancer
NIVOLUMAB (9,987)
CARBOPLATIN (7,939)
PEMBROLIZUMAB (6,893)
OSIMERTINIB (6,358)
PEMETREXED (5,179)
PACLITAXEL (4,609)
ATEZOLIZUMAB (4,459)
BEVACIZUMAB (4,136)
DURVALUMAB (3,396)
ERLOTINIB (3,359)